Intuitive Surgical, Inc. (ISRG) $450.58
Intuitive Surgical stands at a critical juncture, having shed over 25% from its 52-week high and plummeting 24% in the last three months. While the stock’s RSI screams oversold, the technical picture remains murky, urging caution before diving in.
52-wk High $603.88
π Investment Snapshot
- π° ISRG trades at $450.58, a steep 57.25x P/E ratio, despite its $160B market cap.
- π Latest quarter revenue hit $2.87B with $2.21 EPS, demonstrating consistent growth.
- π The stock’s RSI of 23.8 signals extreme oversold conditions, hinting at a potential rebound.
- π― Analysts maintain a Strong Buy consensus with a $602.74 target, implying 33.77% upside.
Intuitive Surgical currently sits near its 52-week low, with technical indicators like RSI flashing deeply oversold signals. However, the upcoming earnings report and a moderate technical confluence score suggest prudence.
| π Entry Zone | $427.84 or below | π Stop-Loss | $420.00 |
| π Adjust If | Price reclaims $460.00 with sustained volume above 1.0x average, confirming a break above recent bearish FVG. | ||
The Investment Case β Why Now?
Intuitive Surgical has seen a dramatic repricing over the past three months, shedding nearly a quarter of its value. This sharp decline, despite consistent revenue and EPS growth, has pushed the stock into deeply oversold territory, making it an intriguing watch for a potential bounce. The market appears to be discounting future growth or reacting to broader sector pressures, creating a divergence between fundamentals and price action.
However, the primary risk lies in the upcoming Q1 2026 earnings report on April 23rd. Any miss on procedure volumes or a cautious outlook on capital expenditures could exacerbate the current downtrend, potentially pushing the stock towards its 52-week low of $427.84. Furthermore, the high 57.25x P/E ratio leaves little room for error in a rising interest rate environment.
π€ Given the significant price drop and oversold RSI, are current growth projections sufficient to justify ISRG’s premium valuation, or does the market anticipate a slowdown in procedure adoption?
π’ Company Overview
| Detail | Value |
|---|---|
| Company | Intuitive Surgical, Inc. |
| Ticker / Exchange | ISRG / NASDAQ |
| Sector / Industry | Healthcare / Medical Instruments & Supplies |
| CEO | Gary S. Guthart |
| Founded / HQ | 1995 / Sunnyvale, California |
π Price Action & Technicals
Inside VA
Recent buy-side sweeps at $458.0, $478.2, and $486.45 failed to hold, indicating weak demand at those levels as price continued to fall.
ISRG currently trades well below its 50-day SMA of $486.74 and 200-day SMA of $505.72, confirming a pronounced bearish trend. These moving averages now act as significant resistance levels, challenging any immediate upside momentum. The stock’s proximity to its 52-week low of $427.84 suggests this level could offer some psychological support, but a breach would open the door to further downside.
The Relative Strength Index (RSI) at 23.8 screams oversold, a level historically associated with potential bounces. However, the MACD, with a value of -11.43 below its signal line of -10.29, still indicates bearish momentum. The ADX, at 41.2, coupled with a dominant -DI of 35.0, confirms the strength of the ongoing downtrend, suggesting that while oversold, the selling pressure remains intense.
Price sits significantly below the Anchored VWAP from October 2025 at $519.07, a key institutional reference point. The Volume Profile’s Point of Control (POC) at $480.65 also looms above current price, reinforcing resistance. This setup indicates that a substantial amount of recent volume occurred at higher prices, trapping buyers and creating overhead supply.
Volume is running well below average at 49% of the 20-day average, signaling lack of conviction from either buyers or sellers at these levels. The recent buy-side liquidity sweeps, while present, failed to reverse the trend, suggesting they were quickly absorbed by sellers. The presence of multiple unfilled bearish FVGs above the current price ($458.92-$460.76, $466.21-$468.5, $511.03-$520.24) points to potential price magnets for a relief rally, but also highlights the extent of recent selling pressure.
π€ Given the strong downtrend confirmed by ADX, can an oversold RSI alone trigger a sustainable reversal, or is a fundamental catalyst required to overcome the current selling pressure?
β Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| ISRG | Intuitive Surgical | 57.25x |
| MDT | Medtronic plc | 28.0x |
| SYK | Stryker Corporation | 33.0x |
| JNJ | Johnson & Johnson | 18.0x |
| S&P 500 | Index Average | 21.0x |
π° Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $2.87B | $2.21 | |
| Q3 2025 | $2.50B | $1.95 | |
| Q2 2025 | $2.44B | $1.81 | |
| Q1 2025 | $2.25B | $1.92 |
Intuitive Surgical generated a robust $0.7B in Free Cash Flow in the latest quarter, demonstrating strong operational efficiency. The company also returned capital to shareholders through $0.2B in buybacks, underscoring management’s confidence and commitment to shareholder value.
Intuitive Surgical has consistently delivered strong revenue growth, with the latest quarter (Q4 2025) reporting $2.87B, up from $2.25B in Q1 2025. EPS has also shown a healthy upward trend, reaching $2.21 in Q4 2025. This fundamental strength contrasts sharply with the recent stock performance, suggesting a potential disconnect between intrinsic value and market sentiment.
π Growth Drivers β What Moves the Stock
- Robotic Surgery Market Expansion π’ Upside Surprise β The global robotic surgery market continues its robust expansion, driven by increasing demand for minimally invasive procedures and technological advancements. ISRG, as the market leader with its da Vinci system, is exceptionally positioned to capitalize on this secular trend.
- New Product Development & Indications π’ Upside Surprise β Continued innovation and expansion into new surgical indications for the da Vinci system, alongside the development of next-generation platforms like Ion, promise to broaden ISRG’s addressable market and sustain long-term growth.
- Recurring Revenue Model π‘ Priced In β A significant portion of ISRG’s revenue stems from recurring sources, including instrument and accessory sales, and service contracts. This stable revenue base provides resilience and predictability, even amidst capital expenditure fluctuations.
π¦ Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 33,613 |
| Blackrock Inc. | 30,516 |
| State Street Corporation | 15,701 |
| Price (T.Rowe) Associates Inc | 12,554 |
| Geode Capital Management, LLC | 8,225 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| CURET MYRIAM J | Officer | Mar 10, 2026 | Other | 105 |
| BROSIUS MARK PRESTON | Officer | Mar 09, 2026 | Other | 1,293 |
| BROSIUS MARK PRESTON | Officer | Mar 05, 2026 | Other | 3,658 |
| CURET MYRIAM J | Officer | Mar 03, 2026 | Other | 4,853 |
| WIDMAN FREDRIK | Officer | Mar 03, 2026 | Other | 367 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 3.9 |
β Key Risk Factors
~$100M+ in deferred revenue
~5% market share erosion
~10-15% price correction
~7-10% immediate drop
π€ Given ISRG’s premium valuation and the looming earnings report, how much downside risk is truly priced in, and what specific metrics would signal a definitive break from the current bearish trend?
π― Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $750.0 | $602.74 | $378.0 | 30 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Evercore ISI Group | In-Line | Apr 2026 | Maintains | |
| UBS | Neutral | Mar 2026 | Maintains | |
| Citigroup | Buy | Mar 2026 | Upgraded | |
| Freedom Capital Markets | Buy | Jan 2026 | Upgraded |
Despite the recent price weakness, the analyst community maintains a strong 'Buy' consensus on ISRG, with a mean price target of $602.74, implying over 33% upside. This collective optimism suggests analysts believe the current downturn is temporary, focusing on the company’s long-term growth prospects and market leadership.
π Bull vs Bear β Probability-Weighted Scenarios
π Bull Case
- Robust demand for robotic-assisted surgery drives consistent procedure volume growth, underpinning ISRG’s recurring revenue streams.
- Deeply oversold technicals (RSI 23.8) and strong institutional support could trigger a sharp rebound, especially if Q1 earnings surprise to the upside.
π Base Case
Our base case anticipates ISRG to consolidate around current levels, potentially testing the $427.84 (52-week low) support before any sustained recovery. The upcoming earnings report will be a critical determinant, with a neutral outcome leading to sideways action. We project a fair value reflecting its growth but acknowledging valuation headwinds.
π» Bear Case
- A miss on Q1 earnings or a cautious outlook on capital expenditures could trigger a breakdown below the 52-week low of $427.84.
- Sustained high interest rates and increased competition could compress margins and slow system adoption, further justifying a de-rating of its premium valuation.
π― Investor Action Plan β By Profile
The technical picture remains too volatile for short-term trades, with strong downtrend momentum overpowering oversold signals. Stay on the sidelines until a clear reversal pattern emerges above $460.00.
While ISRG’s long-term thesis remains compelling, the current price action and upcoming earnings present too much uncertainty. Consider initiating a position only if the stock tests $427.84 or below, or decisively breaks above $460.00 on strong volume post-earnings.
For those with existing positions, the fundamental growth story remains intact, but the current valuation and macro environment warrant caution. Avoid adding to positions until after the Q1 earnings report, and monitor for signs of a technical bottom.
β Investor FAQ β People Also Ask
Q: Why is ISRG’s stock falling despite strong revenue growth?
The recent decline in ISRG’s stock price, despite consistent revenue and EPS growth, likely reflects market concerns over its premium valuation (57.25x P/E) in a rising interest rate environment. Investors may also be anticipating increased competition or a slowdown in capital expenditures by hospitals.
Q: What are the key technical levels to watch for ISRG?
Key levels include the 52-week low at $427.84, which acts as critical support. Overhead resistance is significant at the Volume Profile’s Point of Control (POC) at $480.65 and the 50-day SMA at $486.74. A break above $460.00 could signal a short-term relief rally.
Q: Is the upcoming earnings report a significant risk?
Absolutely. With Q1 2026 earnings scheduled for April 23rd, the report carries high risk. Any deviation from analyst expectations, particularly regarding procedure volumes, system placements, or forward guidance, could significantly impact the stock’s direction given its current volatility and downtrend.
π How has the stock moved since this analysis?
π Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investing in stocks involves risks, including the potential loss of principal. Always conduct your own due diligence and consult with a qualified financial advisor before making any investment decisions. The views expressed herein are those of the author and do not necessarily reflect the views of Goldman Sachs or its affiliates.
All active positions and their real-time performance are tracked on our Investment Log.
#ISRG #IntuitiveSurgical #USStocks #StockAnalysis #HealthcareStocks #RoboticSurgery #MedicalDevices #Veqtio